Sero-diagnosis of <i>Chlamydia trachomatis</i> and Molecular Detection of Genital Oncogenic <i>Human Papilloma Virus</i> Among Cameroonian Women

Bernard Wabo; Dickson Shey Nsagha; Théophile Njamen Nana; Clement Jules Nguedia Assob

doi:doi:10.11648/j.ejcbs.20200605.14

| Peer-Reviewed

Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women

Bernard Wabo, Dickson Shey Nsagha, Théophile Njamen Nana, Clement Jules Nguedia Assob

Published in European Journal of Clinical and Biomedical Sciences (Volume 6, Issue 5)

Received: 19 August 2020 Accepted: 2 September 2020 Published: 16 September 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Cervical cancer is a preventable public health concern ranking second among women’s cancer in Cameroon. Human papilloma virus (HPV) is the main causative agent with Chlamydia trachomatis being suggested as the co-factor. Our objective was to characterize high risk (hr) HPV types and to detect Chlamydia trachomatis antibodies among Cameroonian women with and without cervical cancer. Methods: This unmatched case-control study enrolled 100 cases with cervical cancer and 200 controls with normal cytology aged 25- 65 years in four reference hospitals in Douala and Yaoundé (Cameroon). Consented participants filled a structured questionnaire and data on socio-demographic characteristics collected. Chlamydia trachomatis antibodies were detected by the Enzyme Linked Immuno-Sorbent Assay technique (ELISA) and hr HPV- DNA by PCR technique. Descriptive statistics was conducted to provide frequencies and percentages and the logistic regression analysis to assess the association between categorical data. p < 0.05 was considered significant. Results: Our data showed 39 (39.0%) cases aged 39-52 years compared to 96 (48.0%) controls aged 25-38 years (p=0.001). We found 82 (82.0%) cases compared to 131 (65.5%) controls with hr HPV infections. HPV 16 was most prevalent being found in 29 (29.0%) cases compared to 69 (34.5%) controls. Chlamydia trachomatis IgG / hr HPV co-infections were detected in 20 (20.0%) cases compared to 33 (16.5%) controls but with no significant association with cervical cancer (aOR=1.87; 95%CI: 0.58-5.97; p=0.293). Chlamydia trachomatis IgM (aOR=3.50; 95%CI: 1.16-10.49; p=0.025) was significantly associated with cervical cancer. Conclusion: Hr HPV- DNA was high in cases than in controls. Chlamydia trachomatis single infection and Chlamydia trachomatis/hr HPV co-infections were not significantly associated to precancerous lesions thus, necessitating further investigations.

Published in	European Journal of Clinical and Biomedical Sciences (Volume 6, Issue 5)
DOI	10.11648/j.ejcbs.20200605.14
Page(s)	90-99
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Precancerous Lesions, Human papilloma virus, Chlamydia trachomatis, Co-infection, Case-control Study

References

[1]	Manga MM, Fowotade A, Abdullahi YM, El-nafaty AU, Adamu DB, Pindiga HU, Bakare RA and Osoba AO. Epidemiological patterns of cervical human papillomavirus infection among women presenting for cervical cancer screening in North-Eastern Nigeria. Infect Agents Cancer. 2 October 2015; 10: 39.
[2]	Owki LA, Othieno E, Wandabwa J, Okoth A. Prevalence of cancerous and pre-malignant lesions of cervical cancer and their association with risk factors as seen among women in the regions of Uganda. J Clinic Laboratory Med. 8 Marsh 2017; 2.1.
[3]	Bouassa R-S M, Prazuck T; Lethu T, Jenabian M-A, Meye J-F; Bélec L. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Review of Anti- infective Therapy. 5 May 2017; 15 (6): 613-627.
[4]	Ghittoni R, Accardi R, Chiocca S and Tommasino M. Role of human papilloma viruses in carcinogenesis. ecancer. 29 April 2015; 9: 526.
[5]	Clarke MA, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, Schiffman RBM. A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection. BMC Infect Dis. 8 February 2012, 12: 33.
[6]	Bhatla N, Puri K, Joseph E, Kriplani A, Iyer VK & Sreenivas V. Association of Chlamydia trachomatis infection with human papillomavirus (HPV) & cervical intraepithelial neoplasia - A pilot study. Indian J Med Res. Marsh 2013; 137: 533-539.
[7]	Parthenisa C, Panagopoulosa P, Margarib N, Kottaridib C, Spathis A, Pouliakis A, Konstantoudakis S, Chreliasa G, Chreliasa C, Papantonioua N, Ioannis G. Panayiotides, Tsiodras S. The association between sexually transmitted infections, human papilloma virus, and cervical cytology abnormalities among women in Greece. Intern J Infect Dis. 5 June 2018; 73: 72–77.
[8]	Malhotra M, Sood S, Mukherjee A, Muralidhar S & Bala M. Genital Chlamydia trachomatis: An update. Indian J Med Res. October 2013; 138: 33-316.
[9]	Richard PM. New insights into a persistent problem: Chlamydia infections. J. Clin. Invest. 1 June 2003; 111: 1647–1649.
[10]	Bekolo CE, O’Bryan G, Tchago FE, Nangue C, Bekoule PS, Kollo B. Integrating cervical cancer screening with HIV care in Cameroon: Comparative Risk Analysis of Cervical Disease in HIV-infected women receiving antiretroviral therapy to women in the general Population. PLoS ONE. 11 February 2016, 11 (2): e0149152.
[11]	De Castro-Sobrinho JM, Rabelo-Santos SH, Alves RRF, Derchain S, Sarian LOZ, Pitta DR, Campos EA and Zeferino LC. Chlamydia trachomatis Co-infection in HPV Positive Women brings no Additional Risk of High-grade Cervical Intraepithelial Neoplasia. J Cytol Histol. November 20, 2015, S3: 2.
[12]	Zhu H, Shen Z, Luo H, Zhang W, and Zhu X. Chlamydia Trachomatis Infection- Associated Risk of Cervical Cancer. A Meta-Analysis. Medicine. Marsh 2016: 95 (13): e377).
[13]	Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, and Unger ER. Association of Chlamydia trachomatis with Persistence of High-Risk Types of Human Papillomavirus in a Cohort of Female Adolescents. Am J Epidemiol. January 13, 2005; 162: pp 668-675.
[14]	Tungsrithong N, Kasinpila C, Maneenin C, Namujju PB, Lehtinen M, Anttila A, Promthet S. Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Cancer Risk in a Nested Case-Control Study in North-East Thailand. Asian Pacific J Cancer Prev. 15 July 2014; 15 (3): 1497-1500.
[15]	Charan J and Biswas T. How to Calculate Sample Size for Different Study Designs in Medical Research? Indian J Psychol Med. April- June 2013; 35 (2): 121–126.
[16]	Doh G, Ikomey MG, Njenda D, Gichana J, Katusiime MG, Ndze VN, Zeier M, Mesembe M, Fokunang C, Assoumou OCM, Tebeu PM, Atangana PA, Jacobs GB. Oncogenic Human Papillomavirus Genotypes 16 and 18 Prevalence Among Women with Normal Cervical Cytology and Neoplasia in Cameroon: A Systematic Review. Health Sci. Dis: August- September 2017; 18 (3).
[17]	Debrah O, Agyemang-Yeboah F, Asmah RH, Timmy-Donkoh E, Seini MM, Fondjo LA, Nilok Sight and Owusu-Dabo E. Sero-prevalence of herpes simplex virus type 1 and type 2 among women attending routine Cervicare clinics in Ghana. BMC Infect Dis. 7 August 2018; 18: 378.
[18]	Sankaranarayanan R, Wesley RS. A Practical Manual on Visual Screening for Cervical Neoplasia IARC Technical Publication No. 41 IARC Press, 2003.
[19]	Sharmaa P, Pattanshetty SM. A study on risk factors of cervical cancer among patients attending a tertiary care hospital: A case-control study. Clinic Epidemiol Global Health 6 3 October 2017; 2018; 83-87.
[20]	Mohann P, Shetty S. A Case Control Study on the Risk Factors of Cervical Cancer among Women in a Coastal City of South India. Intern J Sci Research (IJSR). July 2015; 4 (7): 2049-2051.
[21]	Kalgong G, Kamdje NHA, Tagne SR, Nangue C. Sensitivity and specificity of visual inspection with acetic acid (VIA) and with Lugol Iodine (VILI) in the diagnosis of cervical cancer in the Northern Region of Cameroon. Int. Biol. Biomed. J. 25 Marsh 2017; 3 (2).
[22]	Girgis SA, kassem NN and Eltohamy OA. Chlamydia trachomatis and Human Papilloma Virus (HPV) infection in Egyptian Patients with Invasive Cancer Cervix- A Case Control Study. Int. J. Curr. Microbiol. App. Sci. Volume 4 Number 6 (2015) pp. 937-949.
[23]	Damião PDA, Oliveira-Silva M, Moreira MA, Poliakova N, De Lima MERT, Chiovo J, Nicol AF,& Human Papillomavirus types distribution among women with cervical preneoplastic, lesions and cancer in Luanda, Angola. Pan Afr Med J. 22 July 2016; 24: 268.
[24]	Winer RL, Hughes JP, Feng Q, Xi LF, Lee SK, O’Reilly SF, Kiviat NB, and Koutsky LA. Prevalence and risk factors for oncogenic HPV infections in high-risk mid-adult women. Sex Transm Dis. November 2012; 39 (11): 848-856.
[25]	Wohlmeister D, Vianna DRB, Helfer VE, Gimenes F, Consolaro MEL, Barcellos RB, Rossetti ML, Calil LN, Buffon A, Pilger DA. Association of human papillomavirus and Chlamydia trachomatis with intraepithelial alterations in cervix samples. Mem Inst Oswaldo Cruz, Rio de Janeiro. February 2016; 111 (2): 106-113.
[26]	Natphopsuk S, Settheetham-Ishida W, Sinawat S, Pientong C, Yuenyao P, Shida T. Risk factors for cervical in Northern eastern Thaland: detailed analyses of sexual and smoking behaviour. Asian Pacific J cancer. November 2012; 13 (11): 5489-5495.
[27]	Okechukwu A. Ibeanu. Molecular pathogenesis of cervical cancer. Cancer Biol Therapy. 1 February 2011. 11 (3): 295-306.
[28]	Pirek D, Petignat P, Vassilakos P, Gourmaud J, Pache JC, Rubbia-Brandt L, Zacharie Sando Z, McKee, Liza Ho TA. Human papillomavirus genotype distribution among Cameroonian women with invasive cervical cancer: a retrospective study. Sex Transm Infect. 6 Marsh 2015; 91: 440-444.
[29]	Omar VE, Orvalho A, Nália I, Malin K, Gabriella LL, Torbjörn R, Charlotta N, Kerstin F, Nafissa O, Vindorai JI, Sören A. Human papillomavirus prevalence and genotype distribution among young women and men in Maputo city, Mozambique. BMJ Open 17 July 2017; 7: e015653.
[30]	Okunade KS, Nwogu CM, Oluwole AA. Anorlu RI. Prevalence and risk factors for genital high-risk human papillomavirus infection among women attending the outpatient clinics of a university teaching hospital in Lagos, Nigeria. Pan Afr Med J. 14 November 2017; 28: 227.
[31]	Muvunyi CM, Dhont N, Verhelst R, Temmerman M, Claeys G, and Padalko E. Chlamydia trachomatis infection in fertile and subfertile women in Rwanda: prevalence and diagnostic significance of IgG and IgA antibodies testing. Human Reprod. 20 October 2011; 26, (12): 3319-3326.
[32]	Rowley J, Hoorn SV, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, Chico RM, Smolak A, Newman L, Gottlieb S, Thwin SS, Brouteta N & Taylora MM. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 1 August 2019; 97: 548–562.
[33]	Ige OT, Ige SO, Olayinka AT. Prevalence of Chlamydia Trachomatis infection among women of reproductive age group in a tertiary hospital in Northern Nigeria. Ann Trop Pathol. 24 October 2018; 9: 17-21.
[34]	Deluca GD, Schelover JBE, Vásquez ND, Alonso JM, Marín HM, Lucero RH, Picconi MA. Chlamydia trachomatis as a probable cofactor in human papillomavirus infection in aboriginal women from northeastern Argentina. Braz J Infect Dis. November-December 2011; 15 (6): 567-572.
[35]	Pinto VM, Tancredi MV, De Carvalho da Silva RJ, Khoury Z and Buchalla CM. Prevalence and factors associated with Chlamydia trachomatis infection among women with HIV in São Paulo. Rev Soc Bras Med Trop. May-June 2016; 49 (3): 312-318.
[36]	Adegbesan-Omilabu MA, Okunade KS, Oluwole AA, Gbadegesin A, Omilabu SA. Chlamydia trachomatis among women with normal and abnormal cervical smears in Lagos, Nigeria. Int J Reprod Contracept Obstet Gynecol. 21 August 2014; 3 (3): 501-506.
[37]	Kwaśniewska A, Skoczyński M, Korobowicz E, Semczuk M, and Goździcka-Józefiak A. Prevalence of chlamydia trachomatis in cervical and vulvar carcinoma of the Lublin region patients. Bull Vet Inst Pulawy. 18 July 2007; 51: 357-360.
[38]	Naucler P, Chen H-C, Persson K, You S-L, Hsieh C-Y, Sun C-A, Dillner J and Chen C-J. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case–control study. J Gen Virol. 24 November 2007; 88: 814-822.
[39]	Ssedyabane F, Amnia DA, Mayanja R, Omonigho A, Ssuuna C, Najjuma JN, and Freddie B. HPV-Chlamydial Co-infection, Prevalence, and Association with Cervical Intraepithelial Lesions: A Pilot Study at Mbarara Regional Referral Hospital. J Cancer Epidemiol. 10 January 2019: (7).
[40]	Javanmard D, Behravan M, Ghannadkafi M, Salehabadi A, Ziaee M, Namaei MH. Detection of Chlamydia trachomatis in Pap Smear Samples from South Khorasan Province of Iran. Int J Fertil Steril. 15 January 2018; 12 (1): 31-36.
[41]	Silins I, Ryd W, Strand A, Wadell G, To¨rnberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J and Rylander E. Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer. 8 March 2005; 116: 110-115.
[42]	Smelov V, Gheit T, Sundström K, Ploner A, McKay-Chopin S, Eklund C, Tommasino M, Dillner J. Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. PLoS ONE. May 26, 2016; 11 (5): e0156215.

Cite This Article

Plain Text BibTeX RIS

APA Style

Bernard Wabo, Dickson Shey Nsagha, Théophile Njamen Nana, Clement Jules Nguedia Assob. (2020). Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women. European Journal of Clinical and Biomedical Sciences, 6(5), 90-99. https://doi.org/10.11648/j.ejcbs.20200605.14

Copy | Download

ACS Style

Bernard Wabo; Dickson Shey Nsagha; Théophile Njamen Nana; Clement Jules Nguedia Assob. Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women. Eur. J. Clin. Biomed. Sci. 2020, 6(5), 90-99. doi: 10.11648/j.ejcbs.20200605.14

Copy | Download

AMA Style

Bernard Wabo, Dickson Shey Nsagha, Théophile Njamen Nana, Clement Jules Nguedia Assob. Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women. Eur J Clin Biomed Sci. 2020;6(5):90-99. doi: 10.11648/j.ejcbs.20200605.14

Copy | Download

@article{10.11648/j.ejcbs.20200605.14,
  author = {Bernard Wabo and Dickson Shey Nsagha and Théophile Njamen Nana and Clement Jules Nguedia Assob},
  title = {Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women},
  journal = {European Journal of Clinical and Biomedical Sciences},
  volume = {6},
  number = {5},
  pages = {90-99},
  doi = {10.11648/j.ejcbs.20200605.14},
  url = {https://doi.org/10.11648/j.ejcbs.20200605.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20200605.14},
  abstract = {Cervical cancer is a preventable public health concern ranking second among women’s cancer in Cameroon. Human papilloma virus (HPV) is the main causative agent with Chlamydia trachomatis being suggested as the co-factor. Our objective was to characterize high risk (hr) HPV types and to detect Chlamydia trachomatis antibodies among Cameroonian women with and without cervical cancer. Methods: This unmatched case-control study enrolled 100 cases with cervical cancer and 200 controls with normal cytology aged 25- 65 years in four reference hospitals in Douala and Yaoundé (Cameroon). Consented participants filled a structured questionnaire and data on socio-demographic characteristics collected. Chlamydia trachomatis antibodies were detected by the Enzyme Linked Immuno-Sorbent Assay technique (ELISA) and hr HPV- DNA by PCR technique. Descriptive statistics was conducted to provide frequencies and percentages and the logistic regression analysis to assess the association between categorical data. p Results: Our data showed 39 (39.0%) cases aged 39-52 years compared to 96 (48.0%) controls aged 25-38 years (p=0.001). We found 82 (82.0%) cases compared to 131 (65.5%) controls with hr HPV infections. HPV 16 was most prevalent being found in 29 (29.0%) cases compared to 69 (34.5%) controls. Chlamydia trachomatis IgG / hr HPV co-infections were detected in 20 (20.0%) cases compared to 33 (16.5%) controls but with no significant association with cervical cancer (aOR=1.87; 95%CI: 0.58-5.97; p=0.293). Chlamydia trachomatis IgM (aOR=3.50; 95%CI: 1.16-10.49; p=0.025) was significantly associated with cervical cancer. Conclusion: Hr HPV- DNA was high in cases than in controls. Chlamydia trachomatis single infection and Chlamydia trachomatis/hr HPV co-infections were not significantly associated to precancerous lesions thus, necessitating further investigations.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women
AU  - Bernard Wabo
AU  - Dickson Shey Nsagha
AU  - Théophile Njamen Nana
AU  - Clement Jules Nguedia Assob
Y1  - 2020/09/16
PY  - 2020
N1  - https://doi.org/10.11648/j.ejcbs.20200605.14
DO  - 10.11648/j.ejcbs.20200605.14
T2  - European Journal of Clinical and Biomedical Sciences
JF  - European Journal of Clinical and Biomedical Sciences
JO  - European Journal of Clinical and Biomedical Sciences
SP  - 90
EP  - 99
PB  - Science Publishing Group
SN  - 2575-5005
UR  - https://doi.org/10.11648/j.ejcbs.20200605.14
AB  - Cervical cancer is a preventable public health concern ranking second among women’s cancer in Cameroon. Human papilloma virus (HPV) is the main causative agent with Chlamydia trachomatis being suggested as the co-factor. Our objective was to characterize high risk (hr) HPV types and to detect Chlamydia trachomatis antibodies among Cameroonian women with and without cervical cancer. Methods: This unmatched case-control study enrolled 100 cases with cervical cancer and 200 controls with normal cytology aged 25- 65 years in four reference hospitals in Douala and Yaoundé (Cameroon). Consented participants filled a structured questionnaire and data on socio-demographic characteristics collected. Chlamydia trachomatis antibodies were detected by the Enzyme Linked Immuno-Sorbent Assay technique (ELISA) and hr HPV- DNA by PCR technique. Descriptive statistics was conducted to provide frequencies and percentages and the logistic regression analysis to assess the association between categorical data. p Results: Our data showed 39 (39.0%) cases aged 39-52 years compared to 96 (48.0%) controls aged 25-38 years (p=0.001). We found 82 (82.0%) cases compared to 131 (65.5%) controls with hr HPV infections. HPV 16 was most prevalent being found in 29 (29.0%) cases compared to 69 (34.5%) controls. Chlamydia trachomatis IgG / hr HPV co-infections were detected in 20 (20.0%) cases compared to 33 (16.5%) controls but with no significant association with cervical cancer (aOR=1.87; 95%CI: 0.58-5.97; p=0.293). Chlamydia trachomatis IgM (aOR=3.50; 95%CI: 1.16-10.49; p=0.025) was significantly associated with cervical cancer. Conclusion: Hr HPV- DNA was high in cases than in controls. Chlamydia trachomatis single infection and Chlamydia trachomatis/hr HPV co-infections were not significantly associated to precancerous lesions thus, necessitating further investigations.
VL  - 6
IS  - 5
ER  -

Copy | Download

Author Information

Bernard Wabo

Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, Cameroon
Dickson Shey Nsagha

Department of Public Health and Hygiene, Faculty of Health Sciences, University of Buea, Buea, Cameroon
Théophile Njamen Nana

Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of Buea, Buea, Cameroon
Clement Jules Nguedia Assob

Department of Medical Laboratory Science, Faculty of Health Sciences, University of Buea, Buea, Cameroon

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Bernard Wabo, Dickson Shey Nsagha, Théophile Njamen Nana, Clement Jules Nguedia Assob. (2020). Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women. European Journal of Clinical and Biomedical Sciences, 6(5), 90-99. https://doi.org/10.11648/j.ejcbs.20200605.14

Copy | Download

ACS Style

Bernard Wabo; Dickson Shey Nsagha; Théophile Njamen Nana; Clement Jules Nguedia Assob. Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women. Eur. J. Clin. Biomed. Sci. 2020, 6(5), 90-99. doi: 10.11648/j.ejcbs.20200605.14

Copy | Download

AMA Style

Bernard Wabo, Dickson Shey Nsagha, Théophile Njamen Nana, Clement Jules Nguedia Assob. Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women. Eur J Clin Biomed Sci. 2020;6(5):90-99. doi: 10.11648/j.ejcbs.20200605.14

Copy | Download

@article{10.11648/j.ejcbs.20200605.14,
  author = {Bernard Wabo and Dickson Shey Nsagha and Théophile Njamen Nana and Clement Jules Nguedia Assob},
  title = {Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women},
  journal = {European Journal of Clinical and Biomedical Sciences},
  volume = {6},
  number = {5},
  pages = {90-99},
  doi = {10.11648/j.ejcbs.20200605.14},
  url = {https://doi.org/10.11648/j.ejcbs.20200605.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20200605.14},
  abstract = {Cervical cancer is a preventable public health concern ranking second among women’s cancer in Cameroon. Human papilloma virus (HPV) is the main causative agent with Chlamydia trachomatis being suggested as the co-factor. Our objective was to characterize high risk (hr) HPV types and to detect Chlamydia trachomatis antibodies among Cameroonian women with and without cervical cancer. Methods: This unmatched case-control study enrolled 100 cases with cervical cancer and 200 controls with normal cytology aged 25- 65 years in four reference hospitals in Douala and Yaoundé (Cameroon). Consented participants filled a structured questionnaire and data on socio-demographic characteristics collected. Chlamydia trachomatis antibodies were detected by the Enzyme Linked Immuno-Sorbent Assay technique (ELISA) and hr HPV- DNA by PCR technique. Descriptive statistics was conducted to provide frequencies and percentages and the logistic regression analysis to assess the association between categorical data. p Results: Our data showed 39 (39.0%) cases aged 39-52 years compared to 96 (48.0%) controls aged 25-38 years (p=0.001). We found 82 (82.0%) cases compared to 131 (65.5%) controls with hr HPV infections. HPV 16 was most prevalent being found in 29 (29.0%) cases compared to 69 (34.5%) controls. Chlamydia trachomatis IgG / hr HPV co-infections were detected in 20 (20.0%) cases compared to 33 (16.5%) controls but with no significant association with cervical cancer (aOR=1.87; 95%CI: 0.58-5.97; p=0.293). Chlamydia trachomatis IgM (aOR=3.50; 95%CI: 1.16-10.49; p=0.025) was significantly associated with cervical cancer. Conclusion: Hr HPV- DNA was high in cases than in controls. Chlamydia trachomatis single infection and Chlamydia trachomatis/hr HPV co-infections were not significantly associated to precancerous lesions thus, necessitating further investigations.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Sero-diagnosis of Chlamydia trachomatis and Molecular Detection of Genital Oncogenic Human Papilloma Virus Among Cameroonian Women
AU  - Bernard Wabo
AU  - Dickson Shey Nsagha
AU  - Théophile Njamen Nana
AU  - Clement Jules Nguedia Assob
Y1  - 2020/09/16
PY  - 2020
N1  - https://doi.org/10.11648/j.ejcbs.20200605.14
DO  - 10.11648/j.ejcbs.20200605.14
T2  - European Journal of Clinical and Biomedical Sciences
JF  - European Journal of Clinical and Biomedical Sciences
JO  - European Journal of Clinical and Biomedical Sciences
SP  - 90
EP  - 99
PB  - Science Publishing Group
SN  - 2575-5005
UR  - https://doi.org/10.11648/j.ejcbs.20200605.14
AB  - Cervical cancer is a preventable public health concern ranking second among women’s cancer in Cameroon. Human papilloma virus (HPV) is the main causative agent with Chlamydia trachomatis being suggested as the co-factor. Our objective was to characterize high risk (hr) HPV types and to detect Chlamydia trachomatis antibodies among Cameroonian women with and without cervical cancer. Methods: This unmatched case-control study enrolled 100 cases with cervical cancer and 200 controls with normal cytology aged 25- 65 years in four reference hospitals in Douala and Yaoundé (Cameroon). Consented participants filled a structured questionnaire and data on socio-demographic characteristics collected. Chlamydia trachomatis antibodies were detected by the Enzyme Linked Immuno-Sorbent Assay technique (ELISA) and hr HPV- DNA by PCR technique. Descriptive statistics was conducted to provide frequencies and percentages and the logistic regression analysis to assess the association between categorical data. p Results: Our data showed 39 (39.0%) cases aged 39-52 years compared to 96 (48.0%) controls aged 25-38 years (p=0.001). We found 82 (82.0%) cases compared to 131 (65.5%) controls with hr HPV infections. HPV 16 was most prevalent being found in 29 (29.0%) cases compared to 69 (34.5%) controls. Chlamydia trachomatis IgG / hr HPV co-infections were detected in 20 (20.0%) cases compared to 33 (16.5%) controls but with no significant association with cervical cancer (aOR=1.87; 95%CI: 0.58-5.97; p=0.293). Chlamydia trachomatis IgM (aOR=3.50; 95%CI: 1.16-10.49; p=0.025) was significantly associated with cervical cancer. Conclusion: Hr HPV- DNA was high in cases than in controls. Chlamydia trachomatis single infection and Chlamydia trachomatis/hr HPV co-infections were not significantly associated to precancerous lesions thus, necessitating further investigations.
VL  - 6
IS  - 5
ER  -

Copy | Download